BioLight Raises NIS 19 Million, Announces China Regulatory Approval for IOPtiMate™ for Glaucoma Surgery

BioLight announces the successful completion of an equity financing that raised gross proceeds of approximately NIS 19 million (USD 5.5 million).

Separately, BioLight announces that its subsidiary, IOPtima Ltd. a developer of minimally invasive ophthalmic surgery devices, received China Food and Drug Administration (CFDA) approval to market and sell the IOPtiMate™ system in China, the world’s largest glaucoma market.

Link to the complete article

Link to Newsroom

Comments are closed.